Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 5/2021

01.05.2021 | Orthopedic Oncology (JA Abraham, Section Editor)

Giant Cell Tumor of Bone: An Update

verfasst von: Atrayee Basu Mallick, Sant P. Chawla

Erschienen in: Current Oncology Reports | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To highlight the new developments in the management of advanced giant cell tumor of bone, a rare locally aggressive benign tumor, which was traditionally managed with surgery alone by either curettage and local adjuvant therapy, wide resection, or marginal excision. Here, we review the current role of systemic therapy for management of locally advanced or metastatic giant cell tumor of bone (GCTB).

Recent Findings

The elucidation of the pathophysiology of giant cell tumor of bone, especially with regards to the role of nuclear factor kappa B ligand (RANKL), has led to the Food and Drug Administration (FDA) approval of denosumab in the management of locally advanced or metastatic GCTB.

Summary

For advanced giant cell tumor where surgical resection alone can cause severe morbidity, the paradigm has shifted from local treatment alone to multidisciplinary management with the consideration of use of denosumab.
Literatur
1.
Cooper AS, Travers B. Surgical Essays. Longman & Co, London: Cox; 1818.
2.
Jaffe HL, Portis RB. Giant cell tumor of bone. Its pathologic appearance, grading, supposed variants, and treatment. Arch Pathol. 1940;30:993.
3.
Campanacci M, Baldini N, Boriani S, et al. Giant-cell tumor of bone. J Bone Joint Surg Am. 69:106–14.
4.
Larsson SE, Lorentzon R, Boquist L. Giant-cell tumor of bone. A demographic, clinical, and histopathological study of all cases recorded in the Swedish Cancer Registry for the years 1958 through 1968. J Bone Joint Surg Am. 1975;57:167–73.PubMedCrossRef
5.
Baena-Ocampo Ldel C, Ramirez-Perez E, Linares-Gonzalez LM, Delgado-Chavez R. Epidemiology of bone tumors in Mexico City: retrospective clinicopathologic study of 566 patients at a referral institution. Ann Diagn Pathol. 2009;13:16–21.PubMedCrossRef
6.
7.
Viswanathan S, Jambhekar NA. Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities? Clin Orthop Relat Res. 2010;468:827–33.PubMedCrossRef
8.
Unni KK, Inwards CY. Giant cell tumor (osteoclastoma). Dahlins bone tumors: general aspects and data on 10,165 cases. New York: Lippincot William and Wilkins; 2010.
9.
10.
Garcia RA, Inwards CY, Unni KK. Benign bone tumors—recent developments. Semin Diagn Pathol. 2011;28:73–85.PubMedCrossRef
11.
Balke M, Campanacci L, Gebert C, Picci P, Gibbons M, Taylor R, et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone. BMC Cancer. 2010;10:462.PubMedPubMedCentralCrossRef
12.
Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11(5):401–19.PubMedCrossRef
13.
Futamura N, Urakawa H, Tsukushi S, et al. Giant cell tumor of bone arising in long bones possibly originates from the metaphyseal region. Oncol Lett. 2016;11:2629–34.PubMedPubMedCentralCrossRef
14.
• Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11(3):275e80 First study of 37 patient with recurrent or unresectable GCTB to report efficacy of denosumab in the disease.CrossRef
15.
Skubitz K, Thomas D, Chawla S, Staddon A. Response to treatment with denosumab in patients with giant cell tumor of bone (GCTB): FDG PET results from two phase 2 trials. J Clin Oncol. 2014;32(5 Suppl):10505.CrossRef
16.
•• Yamamoto H., Iwasaki T., Yamada Y., Matsumoto Y., et al. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. Hum Pathol. 2018;73 Study highlighting the new developments in the pathologic diagnosis of GCTB. Also sheds light on need for further investigation of this pathway in GCTB.
17.
Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van LP, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45(12):1479e82.CrossRef
18.
Cleven AH, Hocker S, Briaire-de Bruijn I, Szuhai K, Cleton-Jansen AM, Bovee JV. Mutation analysis of H3F3A and H3F3Bas a diagnostic tool for giant cell tumor of bone and chondroblastoma. Am J Surg Pathol. 2015;39(11):1576e83.CrossRef
19.
20.
Liao TS, Yurgelun MB, Chang SS, Zhang HZ, Murakami K, Blaine TA, et al. Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res. 2005;23(1):203–9.PubMedCrossRef
21.
Byers VS, Levin AS, Johnston JO, Hackett AJ. Quantitative immunofluorescence studies of the tumor antigen-bearing cell in giant cell tumor of bone and osteogenic sarcoma. Cancer Res. 1975;35(9):2520–31.PubMed
22.
Goldring SR, Roelke MS, Petrison KK, Bhan AK. Human giant cell tumors of bone identification and characterization of cell types. J Clin Invest. 1987;79(2):483–91.PubMedPubMedCentralCrossRef
23.
Wülling M, Delling G, Kaiser E. The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum Pathol. 2003;34(10):983–93.PubMedCrossRef
24.
Cowan RW, Singh G. Giant cell tumor of bone: a basic science perspective. Bone. 2013;52(1):238–46.PubMedCrossRef
25.
Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175–9.PubMedCrossRef
26.
Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 1997;272:25190–4.PubMedCrossRef
27.
Knochentumoren A, Becker WT, Dohle J, et al. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am. 2008;90:1060–7.CrossRef
28.
Kivioja AH, Blomqvist C, Hietaniemi K, Trovik C, Walloe A, Bauer HCF, et al. Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop. 2008;79:86–93.PubMedCrossRef
29.
Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol. 2008;134(9):969e78.CrossRef
30.
Errani C, Ruggieri P, Asenzio MA, Toscano A, Colangeli S, Rimondi E, et al. Giant cell tumor of the extremity: a review of349 cases from a single institution. Cancer Treat Rev. 2010;36(1):1e7.CrossRef
31.
Khan SA, Kumar A, Inna P, Bakhshi S, Rastogi S. Endoprosthetic replacement for giant cell tumour of the proximal femur. J Orthop Surg (Hong Kong). 2009;17:280–3.CrossRef
32.
Henderson ER, Groundland JS, Pala E, Dennis JA, Wooten R, Cheong D, et al. Failure mode classification for tumor endoprostheses: retrospective review of five institutions and a literature review. J Bone Joint Surg Am. 2011;93(5):418–29.PubMedCrossRef
33.
Shi W, Indelicato DJ, Reith J, Smith KB, Morris CG, Scarborough MT, et al. Radiotherapy in the management of giant cell tumor of bone. Am J Clin Oncol. 2013;36(5):505e8.CrossRef
34.
Rock MG, Sim FH, Unni KK, Witrak GA, Frassica FJ, Schray MF, et al. Secondary malignant giant-cell tumor of bone. Clinicopathological assessment of nineteen patients. J Bone Joint Surg Am. 1986;68(7):1073–9.PubMedCrossRef
35.
Boyle, W. J. et al. Osteoclast differentiation and activation. Nature 423, 337–342
36.
Cheng YY, Huang L, Kumta SM, Lee KM, Lai FM, Tam JSK. Cytochemical and ultrastructural changes in the osteoclast-like giant cells of giant cell tumor of bone following bisphosphonate administration. Ultrastruct Pathol. 2003;27:385–91.PubMedCrossRef
37.
Chang SS, Suratwala SJ, Jung KM, et al. Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis. Clin Orthop Relat Res. 2004;103.
38.
Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, Griffith JF. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone. 2008;42:68–73.PubMedCrossRef
39.
Arpornchayanon O, Leerapun T. Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor: a case report and review of the literature. J Med Assoc Thail. 2008;91:1609.
40.
•• Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14(9):901–8 International open-label parallel-group phase 2 study that led to FDA approval of denosumab in advanced and unresectable GCTB.PubMedCrossRef
41.
Gossai N, Hilgers MV, Polgreen LE, Greengard EG. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer. 2015;62(6):1078e80.CrossRef
42.
•• Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, et al. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long? Eur J Cancer. 2017;76:118–24 Original report on 54 patients who received long-term denosumab (median of 4 years) between 2006 and 2015. It reported an incidence of 9% risk of osteonecrosis of jaw which was found to be dose-dependent.PubMedCrossRef
43.
Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, et al. Current status and unanswered questions onthe use of denosumab in giant cell tumor of bone. Clin Sarcoma Res. 2016;6(1):15.PubMedPubMedCentralCrossRef
44.
Muller DA, Beltrami G, Scoccianti G, Campanacci DA, Franchi A, Capanna R. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series. World J Surg Oncol. 2016;14(1):281.PubMedPubMedCentralCrossRef
45.
Gerrand C, Athanasou N, Brennan B, Grimer R, Judson I, Morland B, et al. UK guidelines for the management of bone sarcomas. Clin Sarcoma Res. 2016;6:7.PubMedPubMedCentralCrossRef
Metadaten
Titel
Giant Cell Tumor of Bone: An Update
verfasst von
Atrayee Basu Mallick
Sant P. Chawla
Publikationsdatum
01.05.2021
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 5/2021
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-021-01047-5

Weitere Artikel der Ausgabe 5/2021

Current Oncology Reports 5/2021 Zur Ausgabe

Breast Cancer (AS Zimmer, Section Editor)

Emerging Therapeutics for Patients with Triple-Negative Breast Cancer

Breast Cancer (AS Zimmer, Section Editor)

Role of Platinums in Triple-Negative Breast Cancer

Interventional Oncology (DC Madoff, Section Editor)

Percutaneous Management of Recurrent Head and Neck Cancer: Current Role and Evolving Principles in the Multidisciplinary Setting

Palliative Medicine (A Jatoi, Section Editor)

Global Perspectives on Palliative Care for Cancer Patients: Not All Countries Are the Same

Breast Cancer (AS Zimmer, Section Editor)

Rare Breast Cancer Subtypes

Breast Cancer (AS Zimmer, Section Editor)

Integrating Adjuvant Radiation with Post-Neoadjuvant Therapies in Early Breast Cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise